MUNICH--(BUSINESS WIRE)--CatalYm today announced that a data update from their ongoing first-in-human trial “GDFather” (GDF-15 Antibody ... Conference on Molecular Targets and Cancer Therapeutics.

In the subset of individuals with cachexia-inducing levels of GDF-15 in their blood, the combination treatment resulted in substantial weight gain ... help to reveal the molecular mechanisms ...

MUNICH--(BUSINESS WIRE)--CatalYm, today announced an update from the dose escalation part of the ongoing first-in-human trial “GDFather” (GDF-15 Antibody-mediated Effector cell Relocation ...

Cachexia manifests as marked involuntary body weight loss, muscle atrophy, and reduced appetite, progressing to significant functional impairment and increased risk of death.¹ Elevated GDF-15 is ...

FL-501 is a potential best-in-class monoclonal antibody targeting growth differentiation factor 15 (GDF-15), a cytokine ... characterized by significant weight loss, muscle wasting, fatigue ...

Ponsegromab increased weight and activity levels in cachexia patients, confirming GDF-15 as a key driver and therapeutic target. Significant weight gain was observed in ponsegromab-treated groups ...

CatalYm today announced that a data update from their ongoing first-in-human trial "GDFather" (GDF-15 Antibody-mediated ... EORTC International Conference on Molecular Targets and Cancer Therapeutics.